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Extracellular matrix components isolated from diabetic mice alter cardiac
ﬁbroblast function through the AGE/RAGE signaling cascade
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Individuals suﬀering from diabetes have an increased risk of developing cardiovascular complications such as
heart failure. Heart failure can be a result of the stiﬀening of the left ventricle, which occurs when cardiac
ﬁbroblasts become “active” and begin to remodel the extracellular matrix (ECM). Fibroblast “activation” can be
triggered by the AGE/RAGE signaling cascade. Advanced Glycation End products (AGEs) are produced and
accumulate in the ECM over time in a healthy individual, but under hyperglycemic conditions, this process is
accelerated. In this study, we investigated how the presence of AGEs in either non-diabetic or diabetic ECM
aﬀected ﬁbroblast-mediated matrix remodeling. In order to address this question, diabetic and non-diabetic
ﬁbroblasts were embedded in 3D matrices composed of collagen isolated from either non-diabetic or diabetic
mice. Fibroblast function was assessed using gel contraction, migration, and protein expression. Non-diabetic
ﬁbroblasts displayed similar gel contraction to diabetic cells when embedded in diabetic collagen. Thus, suggesting the diabetic ECM can alter ﬁbroblast function from an “inactive” to “active” state. Addition of AGEs
increase the AGE/RAGE cascade leading to increased gel contraction, whereas inhibiting the cascade resulted in
little or no gel contraction. These results indicated 1) the ECM from diabetic and non-diabetic mice diﬀer from
one another, 2) diabetic ECM can impact ﬁbroblast function and shift them toward an “active” state, and 3) that
ﬁbroblasts can modify the ECM through activation of the AGE/RAGE signaling cascade. These results suggested
the importance of understanding the impact diabetes has on the ECM and ﬁbroblast function.

1. Introduction
Individuals with hyperglycemia, seen in type I and type II diabetic
patients, are at an increased risk of developing complications, such as
cardiovascular disease [1]. Left ventricular hypertrophy is a common
cardiovascular complication connected to diabetes resulting in poor
heart function [2,3]. A contributing cause to left ventricular hypertrophy is increased cell-mediated remodeling of the myocardial extracellular matrix (ECM) [3]. It has been shown that cardiac tissue from
type II diabetics have increased interstitial ECM accumulation (ﬁbrosis), which was attributed to higher numbers of myoﬁbroblasts
present within the heart [3–5]. Cardiac ﬁbroblasts are one of the predominate cell types of the heart, and they are directly involved in the
synthesis, degradation, and maintenance of the ECM [6]. Cardiac ﬁbroblasts are highly responsive to extracellular and intracellular signaling which alters the impact these cells have on the ECM as well as
stimulates cardiac ﬁbroblasts to diﬀerentiate into myoﬁbroblasts,
characterized by having higher mobility and contractility that are detected by increased cell migration and elevated expression of α-smooth
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muscle action (α-SMA) [4,7,8]. While the extracellular and intracellular
signals mediating myoﬁbroblast transition are becoming better understood, the mechanism by which this occurs is still unclear. Our prior
studies have focused on the AGE/RAGE signaling pathway as a determinant mechanism contributing to ﬁbroblast diﬀerentiation into
myoﬁbroblasts in type II diabetes [6]. The current study seeks to build
further on this work in order to develop a better understanding of extracellular signals stemming from the ECM.
While accumulation of advanced glycation end products (AGEs)
occur naturally over time, their formation and accumulation occur at a
higher and more prevalent rate in diabetic individuals due to hyperglycemia [9,10]. Elevated levels of AGEs in the ECM can result in
increased crosslinking of matrix proteins, such as collagen, contributing
to a more rigid ECM [11]. Increased AGE/RAGE signaling can result in
a reduced ECM elasticity impacting tissue physiological function
[6,12]. For example, type I diabetics have an increased level of AGEs
correlated with stiﬀer heart tissue [12]. In addition, AGEs can induce
intracellular signaling cascades via their receptor, RAGE (receptor for
advanced glycated end products), to stimulate increased growth factor
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2.2. Elevated AGE presence in the extracellular diabetic matrix led to
increased ﬁbroblast contraction of collagen matrix

secretion as well as collagen synthesis through their downstream interactions with ERK1/2 (p42/p44) MAP kinases [13,14]. AGE/RAGE
signaling also acts in a positive feedback manner resulting in increased
RAGE expression [14]. Activation of AGE/RAGE signaling cascade has
been demonstrated to promote myoﬁbroblast transition which increase
ﬁbrosis leading to the development of left ventricle stiﬀness and cardiovascular disease in diabetics [6,15,16].
The combination of glycated ECM, AGE crosslinking, and increased
AGE/RAGE signaling can impact cellular function as well as impair
tissue and organ performance. An elevated presence of ECM AGEs, as
noted with diabetics, has been shown to promote ﬁbroblast to myoﬁbroblast transition, which accelerates ECM remodeling [6,17]. For example, a study by Fowlkes et al. 2013 demonstrated that diabetic cardiac ﬁbroblasts embedded in a neutral collagen matrix displayed higher
expression of α-SMA, a marker for myoﬁbroblasts, which contributed to
increased matrix contraction compared to that of non-diabetic ﬁbroblasts [3]. While this study examined the role of diabetes in altering
ﬁbroblast phenotype and function in a neutral collagen matrix, it did
not examine the reciprocal impact the ECM composition has on ﬁbroblast function. This project aimed to address the gap in knowledge
pertaining to the relationship between the ECM, AGE/RAGE signaling,
and cardiac ﬁbroblasts in type II diabetes. Therefore, we hypothesized
that AGEs within the diabetic ECM will induce myoﬁbroblast transition
via elevated AGE/RAGE signaling resulting in increased remodeling of
the ECM. Utilizing non-diabetic and diabetic cardiac ﬁbroblasts as well
as collagen extracted from diabetic and non-diabetic mice to generate a
3D collagen matrix mimicking in vivo conditions, we were able to assess the changes in ﬁbroblast function and the mechanistic role of AGE/
RAGE signaling.

Fibroblasts incorporated into a 3D collagen matrix exerted changes
to the extracellular matrix via contraction. Using similar conditions as
before, diabetic and non-diabetic ﬁbroblasts embedded in a diabetic
matrix displayed signiﬁcantly more matrix contraction compared to
control (Fig. 2A; one-way ANOVA p = 0.0266). Whereas, prevention of
ERK activation with U0126, which directly inhibits upstream proteins
MEK1 and MEK2, reduced the amount of matrix contraction, but the
amount of matrix contraction was still signiﬁcantly more than U0126
treated control (Fig. 2B; one-way ANOVA p = 0.0028). Non-diabetic
and diabetic ﬁbroblasts signiﬁcantly increased matrix contraction when
embedded in a diabetic matrix treated with exogenous AGEs (Fig. 2C,
one-way ANOVA p = 0.0045). Treatment with both AGEs and U0126
produced results similar to U0126 treated matrices (Fig. 2D; one-way
ANOVA p = 0.0837). The results, taken together, suggested that increased AGEs in the ECM caused ﬁbroblasts to undergo increased matrix contraction.
2.3. Increased exogenous AGEs in diabetic matrices led to signiﬁcantly
elevated α-SMA and RAGE protein expression in cardiac ﬁbroblasts
Changes in ﬁbroblast morphology, organization, and function can
be linked to ﬁbroblasts that have transitioned into an “active” ﬁbroblast
(i.e. myoﬁbroblast), and this transition can be assessed by examination
of changes in α-SMA protein expression (Fig. 3A-D). Non-diabetic ﬁbroblasts in both non-diabetic and diabetic matrix expressed lower levels of α-SMA in untreated as well as in U0126 treated cells (Fig. 3A,
one-way ANOVA p < 0.0001; Fig. 3B, one-way ANOVA p = 0.0640).
When cardiac ﬁbroblasts were treated with exogenous AGEs, non-diabetic ﬁbroblasts embedded in a diabetic matrix expressed signiﬁcantly
more α-SMA compared to similar cells in a non-diabetic matrix (Fig. 3C;
one-way ANVOA p < 0.0001, Dunnett's post hoc p = 0.0113).
Treatment with both U0126 and AGEs led to an increase in α-SMA in
non-diabetic ﬁbroblasts in a diabetic matrix compared to cells embedded in a non-diabetic matrix but the increase was not to the same
level as seen in those treated with AGEs alone (Fig. 3D; one-way
ANOVA p = 0.0162).
Examination of untreated diabetic ﬁbroblasts showed signiﬁcantly
more expression of α-SMA compared to the control (Fig. 3A; Dunnett's
post hoc p < 0.0001). The expression of α-SMA was lower in diabetic
ﬁbroblasts in a diabetic matrix treated with U0126 (Fig. 3B; one-way
ANOVA p = 0.0640). Whereas treatment with AGEs resulted in a signiﬁcant increase in α-SMA expression in diabetic ﬁbroblasts in a diabetic matrix compared to AGE treated control group (Fig. 3C; Dunnett's
post hoc p < 0.0001). Combined treatment of U0126 and AGEs resulted in a signiﬁcant increase, but not to the same level as seen with
AGE treatment alone, in α-SMA expression in diabetic ﬁbroblasts embedded in a diabetic matrix (Fig. 3D; Dunnett's post hoc p = 0.0199).
These results suggested that increased AGEs in the ECM induced an
increased ﬁbroblast to myoﬁbroblast transition. In addition to examining α-SMA expression, RAGE expression was assessed.
RAGE expression can be upregulated through a positive feedback
loop with AGE/RAGE signaling. RAGE expression in non-diabetic ﬁbroblasts embedded in non-diabetic and diabetic matrices were unchanged (Fig. 3E; one-way ANOVA p = 0.0015). Treatment with U0126
did not impact RAGE expression in non-diabetic ﬁbroblasts in nondiabetic or diabetic matrices (Fig. 3F; one-way ANOVA p = 0.0006).
RAGE expression signiﬁcantly increased when treated with exogenous
AGEs in non-diabetic ﬁbroblasts in a diabetic matrix compared to the
AGE treated control (Fig. 3G; one-way ANOVA p = 0.0169, Dunnett's
post hoc p = 0.0115). U0126 and AGE combined treatment resulted in
low RAGE expression in non-diabetic ﬁbroblasts in both non-diabetic
and diabetic matrices (Fig. 3H).
In contrast to non-diabetic ﬁbroblasts, diabetic ﬁbroblasts displayed

2. Results
2.1. AGEs within the extracellular matrix induced morphological and
organizational changes in isolated cardiac ﬁbroblasts
In order to examine the impact of AGEs within the extracellular
matrix, diabetic and non-diabetic cardiac ﬁbroblasts were embedded in
a 3D collagen matrix composed of isolated tail collagen from either
diabetic or non-diabetic mice. We found that diabetic tail collagen
contained higher levels of CMLs and AGEs compared to non-diabetic
collagen (Fig. 1A). Elevated levels of AGEs in the diabetic matrix correlated with an increased cell aggregation and a ﬂattened cell morphology in both ﬁbroblast genotypes (Fig. 1B). These changes were not
apparent when both cell types were separately placed in a non-diabetic
matrix. For ﬁbroblasts embedded in a diabetic matrix, the addition of
exogenous AGEs to the matrices resulted in an increase in incidents of
morphological changes in cellular phenotypes. AGE-induced morphological changes were also noted in diabetic cells, and to a lesser degree
in non-diabetic ﬁbroblasts embedded in a non-diabetic matrix, suggesting AGEs in the ECM are capable of inﬂuencing ﬁbroblast behavior.
Diabetic matrix-mediated alterations were not limited to changes in
cell morphology and aggregation. Fibroblasts embedded in the 3D
collagen matrix rearranged themselves to form an interconnected network (Fig. 1C). This circular contractile ring structure was primarily
located near the perimeter of the gel matrix, and both non-diabetic and
diabetic ﬁbroblasts formed this contractile ring structure when embedded in diabetic matrices (Fig. 1C: 1Ce & 1Cg) as well as non-diabetic
matrices (Fig. 1C: 1Ca & 1Cc). Within the interconnective network the
ﬁbroblasts extended cellular processes to adjacent cells (Fig. 1C: 1Cb,
1Cd, 1Cf, & 1Ch; white arrowheads), which resulted in cell-cell connections. While both non-diabetic and diabetic ﬁbroblasts formed the
ring structure, the time in which formation occurred diﬀered (Fig. 1D).
Fibroblasts embedded in a diabetic matrix formed the ring structure
1–2 h faster than cells embedded into a non-diabetic matrix.
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Fig. 1. AGEs within the extracellular matrix induced morphological and organizational changes in isolated cardiac ﬁbroblasts. A) Immunoﬂuorescence staining
(100×; scale bar = 50 μm) revealed elevated levels of carboxymethyl lysine (CML) and advanced glycation end-products (AGEs) in diabetic collagen matrices absent
of ﬁbroblasts. B) Bright ﬁeld images (100×; scale bar = 100 μm) of non-diabetic (non-db) and diabetic (db) cardiac ﬁbroblasts embedded in collagen matrices from
non-db or db mice. Matrices treated with exogenous AGEs had higher numbers of ﬂattened cell morphology (black arrowheads) as well as increased cell aggregation
(red asterisks). C) Non-db and db ﬁbroblasts in collagen matrices were labeled with phalloidin (actin-cytoskeleton, red) and DAPI (DNA-nuclei, blue). Fibroblasts
appeared to organize into connecting ring structures within the collagen matrix (100×; scale bar = 100 μm). Boxes indicate areas of interest at 200×, white arrows
indicate cellular connections between ﬁbroblasts. D) Bright ﬁeld images (40×) were taken to demonstrate the time course for cardiac ﬁbroblasts (non-db and db) to
form initial ring structures in non-db and db matrices. Dashed black lines and red arrows indicate initial cell ring organization. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)

non-diabetic and diabetic matrices exhibited signiﬁcantly higher RAGE
expression compared to U0126 treated control (Fig. 3F; one-way
ANOVA p = 0.0006). Treatment with AGEs led to a signiﬁcantly
greater RAGE expression in diabetic ﬁbroblasts in non-diabetic and

signiﬁcantly higher RAGE expression when embedded in both nondiabetic and diabetic matrices compared to the control (Fig. 3E; oneway ANOVA p = 0.0015). This pattern of elevated RAGE expression
remained the same with treatment of U0126. Diabetic ﬁbroblasts in
3
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Fig. 2. Elevated AGE presence in the extracellular diabetic matrix led to increased ﬁbroblast contraction of collagen matrix. Non-diabetic (non-db) and diabetic (db)
ﬁbroblasts were embedded in non-db and db matrices. Matrix contraction for A) Untreated, B) U0126 treated (5 μM), C) AGE treated (0.5 mg/mL), and D)
AGE + U0126 treated matrices were determined by measuring the area of the ﬁbroblast contractile ring and normalized to the area of the contractile ring from nondb ﬁbroblasts embedded in non-db matrix. Control was set a 0 with a positive value indicating less matrix contraction (larger ring area) while a negative value
denotes more matrix contraction (smaller ring area). Representative matrix images, displayed above graphs, were from the same plate but arranged in a diﬀerent
order to match graph depiction. Data are mean ± SEM, n = 7–10, and statistical analysis consisted of a one-way ANOVA followed by a Dunnett's post hoc
(*p < 0.05, **p < 0.01, ***p < 0.001).

diabetic ﬁbroblasts in non-diabetic matrix (one-way ANOVA
p < 0.0001, Dunnett's post hoc p < 0.0001). Inhibition of RAGE
signaling through pharmacological means had a broad impact on AGE/
RAGE-mediated matrix contraction and protein expression; however,
further studies were undertaken to determine if genetic knockdown of
RAGE directly inhibited AGE/RAGE signaling and matrix contraction in
cardiac ﬁbroblasts.

diabetic matrices compared to AGE treated control (Fig. 3G; one-way
ANOVA p = 0.0169). However, the overall expression of RAGE in
diabetic ﬁbroblasts was lower with AGE treatment compared to diabetic
ﬁbroblasts in untreated and U0126 treatment. Combined U0126 and
AGE treatment resulted in lower RAGE expression in diabetic ﬁbroblasts in a non-diabetic matrix and did not signiﬁcantly diﬀer from the
U0126 and AGE treated control (Fig. 3H; one-way ANOVA
p < 0.0001). Whereas diabetic ﬁbroblasts in a diabetic matrix treated
with U0126 and AGEs did signiﬁcantly express more RAGE than non-

Fig. 3. Increased exogenous AGEs in diabetic matrices led to signiﬁcantly elevated α-SMA and RAGE protein expression in cardiac ﬁbroblasts. Quantiﬁcation of
western blot analysis for α-SMA (42 kDa; A-D) and RAGE (43 kDa; E-H) protein expression was normalized to total protein (Coomassie stain) in untreated, U0126
treated (5 μM), AGE treated (0.5 mg/mL), and AGE + U0126 treated matrices. Data are means ± SEM with n = 3–6 of independent repeats. Representative western
blot images shown above ﬁgures are not displayed as a continuous blot due to running order, but all were run on the same blot. Statistical analysis consisted of a oneway ANOVA with a Dunnett's post hoc (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
4
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Fig. 4. Knockout of RAGE signaling prevented AGE induced ﬁbroblast matrix contraction in diabetic matrix. Non-diabetic (non-db) and non-diabetic RAGE knockout
(non-db RKO) ﬁbroblasts were embedded in non-db and db collagen matrices. Area of the contractile ring for each treatment group (A:U0126 [5 μM], B:AGE [0.5 mg/
mL], and C:AGE + U0126 treated) were measured and normalized to the ring area of the genotypic control on non-db matrix. Contraction of the control treatment
was set a 0 with positive values indicating decreased contraction (larger ring area) and a negative value indicating increased matrix contraction (smaller ring area).
Pictures are representative of matrix images for each treatment group (images are from same plate and gaps are due to proper alignment of images with graphs) and
images for non-diabetic ﬁbroblasts with functional RAGE were used in Fig. 2. Data are mean ± SEM, n = 6–10. Statistical signiﬁcance determined by one-way
ANOVA followed by a Sidak's post hoc (*p < 0.05, ***p < 0.001).

these results, non-diabetic RKO ﬁbroblasts did not display a signiﬁcant
increase in α-SMA expression in controls (Sidak's post hoc p = 0.9994),
U0126 treated (Sidak's post hoc p = 0.6474), AGE treated (Sidak's post
hoc p = 0.9863) or combined U0126 + AGE treated (Sidak's post hoc
p = 0.8219) when embedded in a diabetic matrix compared to being
embedded into a non-diabetic matrix (Fig. 5). Western blot analysis for
RAGE expression was done for non-diabetic RKO ﬁbroblasts embedded
in non-diabetic and diabetic matrices but was not detected due to RAGE
being knocked out in these animals (DOI: https://doi.org/10.6084/m9.
ﬁgshare.11299253). These results indicated that AGE/RAGE signaling
is responsible for myoﬁbroblast transition induced by AGEs in the ECM.

2.4. Knockout of RAGE signaling prevented AGE-induced ﬁbroblast matrix
contraction in diabetic matrix
Knocking out RAGE prevented the impact of diabetic matrix and
AGEs on ﬁbroblast function. Cardiac ﬁbroblasts isolated from RAGE
knockout mice (RKO) were embedded into non-diabetic and diabetic
matrices and matrix contraction was determined and compared to nondiabetic ﬁbroblasts that have a functioning RAGE receptor (data previously shown in Fig. 2). As shown previously, non-diabetic ﬁbroblasts
with functioning RAGE embedded in a diabetic matrix exhibited signiﬁcantly more matrix contraction in both U0126 treated (Fig. 4A; oneway ANOVA p = 0.0344, Sidak's post hoc p = 0.0124) and AGE treated
(Fig. 4B; one-way ANOVA p = 0.0004, Sidak's post hoc p = 0.0001)
matrices compared to the control. Non-diabetic ﬁbroblasts also displayed slightly more, but not signiﬁcantly diﬀerent, matrix contraction
when treated with both U0126 and AGE (Fig. 4C; one-way ANOVA
p = 0.1809, Sidak's post hoc p = 0.1124). In contrast, non-diabetic
RKO ﬁbroblasts embedded in diabetic matrices did not display signiﬁcant increases in matrix contraction when treated with U0126 (Sidak's post hoc p = 0.5112), AGE (Sidak's post hoc p = 0.5804), or
AGE + U0126 (Sidak's post hoc p = 0.6359) compared to non-diabetic
matrices containing RKO ﬁbroblasts (Fig. 4). This data suggested that
inhibition of AGE/RAGE signaling in cardiac ﬁbroblasts prevented the
amount of matrix contraction otherwise noted in ﬁbroblasts with intact
functioning RAGE.

3. Discussion
The results presented in this study demonstrated that a reciprocity
exists in which the elevated presence of AGEs in the ECM can 1) act in a
signal transduction manner to amplify the cardiac ﬁbroblast to myoﬁbroblast phenotype transition through the RAGE cascade and 2) change
cellular function to outwardly modify the surrounding ECM resulting in
increased matrix contraction. The results presented in this study indicate that elevated presence of AGEs in the diabetic ECM induce ﬁbroblasts to transition into myoﬁbroblasts, and this transition is noted
by increased α-SMA expression and greater matrix contraction.
3.1. The impact of the ECM on cardiac ﬁbroblasts

2.5. Knockout of RAGE prevented increases in α-SMA expression in
exogenously AGE treated matrices

A higher prevalence of AGE-crosslinked collagen in the ECM greatly
impacted cardiac ﬁbroblast morphology and organization. Elevated
AGE levels have been demonstrated to occur in individuals with diabetes due to chronic hyperglycemia [9,18]. As we reported, collagen
extracted from diabetic mice had higher concentrations of AGEs and
CMLs compared to collagen isolated from non-diabetic counterparts.
Increased levels of AGEs present in the collagen can impact ECM
structural properties by reducing matrix elasticity and thus increased its
stiﬀness [19,20]. The physical presence of AGEs and changes in matrix
properties perpetuated by AGEs was shown to induce morphological
changes in embedded cardiac ﬁbroblasts. When both non-diabetic and
diabetic cardiac ﬁbroblasts were exposed to higher levels of AGEs, as
those present in diabetic matrices, there were increased cell aggregation as well as a higher number of cells displaying a more ﬂatten

α-SMA expression from non-diabetic RKO ﬁbroblasts embedded into
non-diabetic and diabetic matrix was compared to non-diabetic ﬁbroblasts with RAGE (previously shown in Fig. 3). As shown previously,
non-diabetic ﬁbroblasts with RAGE exhibited low α-SMA expression in
control and U0126 treated groups (Fig. 5A&B). AGE treatment caused a
signiﬁcant increase in α-SMA expression in non-diabetic ﬁbroblasts in a
diabetic matrix compared to those embedded into a non-diabetic matrix
(Fig. 5C; one-way ANOVA p = 0.0141, Sidak's post hoc p = 0.0086). A
similar, but not signiﬁcant, increase in α-SMA expression was noted in
non-diabetic ﬁbroblasts in a diabetic matrix compared non-diabetic
matrix when treated with both AGE and U0126 (Fig. 5D). Contrary to
5
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Fig. 5. Knockout of RAGE prevented increases in α-SMA-expression in exogenous AGE treated matrices. Non-diabetic (non-db) and non-diabetic RAGE knockout
(non-db RKO) ﬁbroblasts were embedded in non-db and db matrices. α -SMA (42 kDa) expression was assessed via western blot analysis and normalized to total
protein (Coomassie stain) for A) untreated, B) U0126 treated (5 μM), C) AGE treated (0.5 mg/mL), D) and AGE + U0126 treated. Representative western blot images,
depicted above graph, are not presented as a continuous blot due to the order of the graph but were run on the same western blot. Western blot images for nondiabetic ﬁbroblasts were also presented in Fig. 3. Data are mean ± SEM with n = 3–5 independent repeats for each group. One-way ANOVA with Sidak's post hoc
determined signiﬁcant diﬀerence (*p < 0.05).

vivo environment, meaning cardiac ﬁbroblasts from a diabetic animal
may have been primed to more easily transition to a myoﬁbroblast
phenotype. Previous studies have demonstrated that diabetic cardiac
ﬁbroblasts embedded in a 3D matrix have higher expression of α-SMA
[3]. Therefore, higher α-SMA expression levels was used as an indicator
of growing myoﬁbroblasts populations, and functionally, these cells
were characterized by increased contractility [7]. With increased contraction as noted in earlier experiments, diabetic ﬁbroblasts could more
readily diﬀerentiate into myoﬁbroblasts [7]. Additionally, we observed
that non-diabetic ﬁbroblasts embedded in a diabetic matrix displayed
comparable matrix contraction to that of diabetic ﬁbroblasts embedded
in a diabetic matrix. This increased contraction was not dependent on
the presumed stiﬀness of the diabetic matrix. Howard et al. 1996
showed glycated matrices displayed less contractility than their nonglycated counterparts, and these researchers attributed matrix stiﬀness
to decreased contraction [26]. Our data suggests that matrix stiﬀness
was not the driving force behind increased contraction, but rather
changes were due to AGEs within the matrix causing increased RAGE
signaling in the cardiac ﬁbroblasts. Further studies will need to be
performed to determine if changes in rheological properties of the
matrices impact ﬁbroblast behavior.
When non-diabetic and diabetic ﬁbroblasts were embedded in a
diabetic matrix the combined exposure to AGEs present in the diabetic
collagen and to exogenous AGE treatments increased activity of the
AGE/RAGE signaling cascade resulting in a signiﬁcant rise in contractility. Interruption of the AGE/RAGE signaling axis with prevention
of ERK1/2 activation, via U0126 inhibition MEK 1 & 2, reduced the
levels of matrix contraction in non-diabetic cells in both matrix types as
well as diabetic ﬁbroblasts in non-diabetic matrix. Phosphorylation of
ERK1/2 is not limited to activation of AGE/RAGE signaling; however,
matrix contraction was most likely not inﬂuenced by other signaling
cascades. Considering the results noted in studies when cells, treated
with combined AGE and U0126, had reduced matrix contraction even
in the presence of exogenous AGEs. While long exposure to exogenous
AGEs should have overcome U0126 inhibition due to half-life of drug
activity, we observed contraction occurred early in the matrix remodeling process. We speculate ERK1/2 is activated rapidly during ﬁbroblast matrix contraction, and U0126 treatment during this critical
period prevented AGE-induced matrix contraction [27]. While ERK1/2
inhibition reduced matrix contraction in most groups, diabetic ﬁbroblasts in a diabetic matrix retained greater matrix contraction despite
U0126 treatment. Thus, indicating there was more AGE/RAGE signaling within diabetic cells to potentially override ERK1/2 inhibition
and induce matrix contraction. Alternatively, we observed RAGE KO
cells had reduced matrix contraction. Knocking out RAGE signaling in

morphology. These physical changes were considered to be a result of
increased AGEs within the matrices triggering activation of the RAGE
signaling cascade. In fact, treatment of diabetic ﬁbroblasts in non-diabetic matrices with AGEs led to increased changes is cell aggregation
and morphology. Previous studies have demonstrated that treatment
with AGEs accelerated the epithelial-myoﬁbroblast transition and induced a ﬂatten ﬁbroblast morphology described as a myoﬁbroblast
[21]. While the presence of AGEs in the ECM can induce physical
changes in cardiac ﬁbroblasts, they also promoted organizational
changes [22,23].
Elevated AGEs in the ECM caused changes in cardiac ﬁbroblast organization within the 3D collagen matrix. Non-diabetic and diabetic
cardiac ﬁbroblasts formed an interconnective network within the matrix, referred to as a contractile ring. The formation of the contractile
ring structure occurred in every treatment group; however, the rate at
which it formed was accelerated when cells were embedded in diabetic
conditions. Diabetic ﬁbroblasts also formed the contractile ring structure faster than non-diabetic ﬁbroblasts. Other labs have previously
demonstrated that diabetic cardiac ﬁbroblasts migrate faster than nondiabetic ﬁbroblasts when plated on neutral collagen [3]. The increased
migration noted in diabetic ﬁbroblasts in our studies may have led to
faster formation of the contractile ring structure. Interestingly, we
found the formation of the contractile ring occurred more rapidly when
ﬁbroblasts, both non-diabetic and diabetic, were embedded in a diabetic matrix. One plausible explanation for increased migration is that
diabetic matrices contain elevated amounts of AGEs, which could induce AGE/RAGE signaling within the cardiac ﬁbroblasts leading cells
toward myoﬁbroblast diﬀerentiation [24]. A study by Vicens-Zygmunt
et al. 2015 showed lung ﬁbroblasts embedded in AGE-crosslinked matrices had increased α-SMA expression, indicating increased myoﬁbroblast population [25]. Thus, lending support to our ﬁndings, that
AGEs within the diabetic matrix can induce myoﬁbroblast transition via
RAGE signaling resulting in increased migration and contractile ring
formation. While the composition of the ECM can act as an inward
signaling stimulus to impact ﬁbroblast function, it also can activate
ﬁbroblasts to outwardly modify their surrounding environment.
3.2. The impact of cardiac ﬁbroblasts on the ECM
While diabetic cardiac ﬁbroblasts exhibited greater overall matrix
contraction, this phenomenon occurred when diabetic cells were placed
in either non-diabetic or diabetic collagen matrices. Thus, demonstrating these cells possess “programmed” capable of orchestrating alterations to both non-diabetic and diabetic matrices. This ability could
be attributed to the cell characteristics retained from the diabetic in
6

Life Sciences 250 (2020) 117569

S.D. Burr and J.A. Stewart

4. Methods

Table 1
Physiological measurements of mice used in in vitro experiments. Data consists
of average values from mice that were used to isolate cardiac ﬁbroblasts with an
average of 2–3 hearts per isolation. Statistical analysis using a one-way ANOVA
followed by a Dunnett's post hoc determined signiﬁcance diﬀerence compared
to non-diabetic mice (*p < 0.05, ****p < 0.0001).

Non-diabetic
Diabetic
Non-diabetic
RKO

Body weight (g)

Blood glucose
(mg/dL)

Heart weight (mg)

28.32 ± 0.55
50.09 ± 1.23 ****
31.64 ± 0.67 *

232 ± 7.9
519 ± 24.4 ****
220 ± 5.8

0.104 ± 0.002
0.120 ± 0.008
0.113 ± 0.004

4.1. Animal model
Experiments were conducted using 16 week old male Leprdb (db/db)
type II diabetes mellitus mice (BKS.Cg-Dock7m +/+ Leprdb/J, Jackson
Labs) and heterozygous mice (db/wt; non-diabetic) were used as lean
controls. The Leprdb mice have a point mutation in the leptin receptor,
resulting in a nonfunctional receptor. The loss of function of the leptin
receptor leads to obesity and insulin resistance, which manifests into
hyperglycemia by 8 weeks of age and diabetes by 12 weeks of age. In
addition, 16 week old male non-diabetic homozygous RAGE knockout
mice (RKO) were used for this study. RKO mice were generated by
ﬂanking exons 2–7 with two loxP sites in the same orientation and when
exposed to Cre recombinase, the loxP and exons 2–7 were deleted
[34–36]. This results in a loss of global RAGE mRNA expression and in
turn RAGE signaling in these mice. In addition, a reversely-oriented
transcriptional EGFP reporter gene was inserted into intron 1, which is
used as a positive control for RAGE knockout mice [34–36]. Breeder
RKO mice were a generous gift from Dr. Pamela Lucchesi and Dr. Angelika Bierhaus. All mice were housed with 12 h/12 h light/dark cycle
and were fed standard chow and tap water ad libitum. All experiments
followed the guidelines of the National Institutes of Health “Guide for
the Care and Use of Laboratory Animals,” and protocols (protocol
#17–024) were approved by The University of Mississippi IACUC
committee. Mice were anesthetized with CO2 exposure followed by
cervical dislocation. After anesthetization, body weight and blood
glucose measurements were taken followed by quick excision of the
heart, which was used for cellular experiments (Table 1).

cardiac ﬁbroblasts restored matrix contraction to levels noted in control
cells (non-diabetic ﬁbroblasts embedded in a non-diabetic matrix). Indicating AGE/RAGE signaling is a key mechanism responsible for increased matrix contraction and myoﬁbroblast diﬀerentiation.
AGE treated diabetic and non-diabetic ﬁbroblasts embedded in
diabetic matrices displayed signiﬁcantly more α-SMA protein expression than controls. Changes in α-SMA expression did not occur when
ﬁbroblasts were treated with U0126 or in RKO ﬁbroblasts, indicating
elevated AGE/RAGE signaling denotes increased myoﬁbroblast transition. Additional to marking myoﬁbroblast presence, increased levels of
α-SMA suggested changes to the contractile apparatus had occurred
within a cell. Previous studies have demonstrated increased expression
of α-SMA correlated with increased matrix contraction [28,29]. While
non-diﬀerentiated cardiac ﬁbroblasts are able to contract the collagen
matrix, additional matrix contraction, past that of “normal” remodeling, would require the presence of myoﬁbroblasts [30]. In addition to α-SMA expression, we examined RAGE expression within the
treatment groups. RAGE expression is regulated by a positive feedback
loop where increased RAGE signaling results in increased RAGE expression [31]. There was elevated RAGE expression in diabetic ﬁbroblasts compared to non-diabetic ﬁbroblasts in most treatment groups.
These ﬁndings suggest diabetic ﬁbroblasts maintained an elevated level
of RAGE expression within the in vitro cell culture model, which was
mostly likely similar to that found in an in vivo setting [32]. The higher
expression of RAGE in diabetic ﬁbroblasts represents a maintenance of
an in vivo phenotype, since RAGE is elevated with diabetes [6]. The
preservation of RAGE expression in diabetic ﬁbroblast cultures could
also explain the signiﬁcantly higher α-SMA expression levels found in
untreated diabetic ﬁbroblasts embedded in a diabetic matrix [33].
Though RAGE expression was high in diabetic cells treated with U0126,
it did not translate into elevated levels of α-SMA. This is due to U0126
eﬀectively inhibiting the AGE/RAGE signaling cascade in these diabetic
cells and prevented an increase in α-SMA (i.e. myoﬁbroblast transition).
The key ﬁndings of this study indicated elevated levels of AGEs
within the ECM, as observed in diabetics, can induce ﬁbroblast to
myoﬁbroblast transition resulting in increased matrix contraction
marked by elevated α-SMA expression. High levels of AGEs in diabetic
matrices induced morphological changes in both non-diabetic and
diabetic cardiac ﬁbroblasts. These physical changes, in combination
with organizational rearrangements, resulted in greater matrix contraction that was due to increased myoﬁbroblast transition [7]. Inhibition of AGE/RAGE signaling via pharmacological methods as well
as a knockout RAGE model prevented increased matrix contraction and
ﬁbroblast diﬀerentiation. Overall, this study highlights the reciprocal
relationship between the ECM and cardiac ﬁbroblasts under diabetic
conditions in which increased AGE presence caused a shift in ﬁbroblast
phenotype to impact matrix contraction. Utilizing these results, we can
gain a better understanding of how cardiac ﬁbroblasts exposed to elevated AGEs contribute to stiﬀening of the left ventricle and poor heart
function in diabetics.

4.2. Fibroblast isolation and culture
Cardiac ﬁbroblasts were isolated from hearts via collagenase-trypsin
enzymatic solution (0.1% Trypsin, Gibco; 100 U/mL collagenase II,
Worthington Biochemical) [6]. Three hearts were used per one ﬁbroblast isolation, whereby one isolation equaled one sample (n = 1).
Fibroblasts were cultured in DMEM media (Dulbecco's Modiﬁed Eagles
Medium [DMEM], sodium pyruvate, L-glutamine, and supplemented
with 14.2 mM NaHCO3, 14.9 mM HEPES, 15% heat-inactivated fetal
bovine serum [FBS], 1% L-glutamine, and 0.02% Primocin [Thermo
Fisher]) and speciﬁcally non-diabetic ﬁbroblasts were cultured in low
glucose DMEM (1 g glucose/L) and diabetic ﬁbroblasts in high glucose
DMEM (4.5 g glucose/L). Fibroblasts were maintained in 5% CO2 incubator at 37 °C. Cells were passaged just prior to reaching 95% conﬂuency using 0.25% trypsin, 0.1% ethylenediaminetetraacetic acid
(trypsin/EDTA) solution (Life Technology). Passage 1 ﬁbroblasts were
used in experiments and were serum starved (0.01% FBS) for 24 h
before use. For this study the descriptive terms diabetic and non-diabetic
associated with the cells used in this study are used to delineate the
source of the ﬁbroblasts and does not imply they are diabetic or nondiabetic.
4.3. Collagen extraction
Collagen was extracted from tails from 16 week old non-diabetic
and diabetic mice [37]. Tails were collected at time of euthanasia and
stored at -20 °C until use. The skin was removed from the tail to expose
the 4 major tendons. Tendons were removed and placed in 150 mL
acetic acid (1:1000 dilution in dH2O) and were cut into small ~5 mm
pieces. The tendon solution was mixed for 3 days at 4 °C. All steps,
hereinafter, were conducted in sterile conditions. After 3 days, the
tendon-acetic acid solution was centrifuged at 3000 xg for 30 min at
4 °C to pellet debris. Supernatant was removed and centrifuged, again,
under the same conditions. The collagen supernatant was removed and
stored at 4 °C. Collagen concentration was estimated using Sircol™
Soluble Collagen Assay Kit (Biocolor Ltd) as per manufacturer's
7
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histology grade 4% paraformaldehyde (Fisher Scientiﬁc). Fibroblasts
and matrix were incubated in blocking solution (3% donkey serum
[Fisher Scientiﬁc], 2% BSA [Fisher Scientiﬁc], 0.01% Trition X-100 in
1× PBS) overnight at 4 °C. Primary antibody was added to matrix and
incubated overnight at 4 °C. Advanced glycated end product (AGE)
antibody (1:50; Abcam ab23722) and carboxymethyl lysine (CML)
antibody (1:50; Abcam ab30917) were added to matrices without cells.
Directly conjugated phallodin-cy3 (1:20; Thermo Fisher) was added to
matrices with embedded ﬁbroblasts. After primary antibody incubation, matrices with ﬁbroblasts had DAPI (1:1000; Fisher Scientiﬁc)
added for 1.5 h at room temperature in the dark in order to visualize the
nucleus. Matrices were imaged using a Nikon Eclipse Ti2 microscope
with pco.edge camera (PCO).

directions.
4.4. 3-Dimensional collagen matrix
Collagen discs were prepared by slowly combining collagen
(2.9 mg/mL), 10× minimum essential media (MEM, Thermo Fisher),
and 0.2 M HEPEs on ice in an 8:1:1 ratio [38]. This was done for both
non-diabetic and diabetic collagen. The collagen solution was placed on
ice in a desiccator and degassed for 10 min to remove air bubbles.
Following removal of air bubbles, equal volumes of the collagen solution and ﬁbroblast cell suspension were combined. The collagen solution containing ﬁbroblasts was plated 1 mL of solution per well in a 24
well plate. Collagen/ﬁbroblast solution was incubated for 1 h at 37 °C
to allow the 3D collagen matrix to polymerize in a disc. After matrix
polymerization, the collagen disc was dislodged from the sides of the
well and 1 mL of starving media was added to each well. AGE (0.5 mg/
mL, Sigma Aldrich) and U0126 (5 μM, Sigma Aldrich) were added to
the appropriate well and was incubated for 7 days at 37 °C. During the
incubation period, the media was not changed, and no additional dosage of drugs occurred. Again, we have chosen to use the descriptive
terms diabetic and non-diabetic with the extracellular matrix collagen in
this study to deﬁne the source of the matrices and does not imply they
are diabetic or non-diabetic.

4.8. Statistical analysis
Graph Prism software, version 8.1.1 was used for statistical analysis.
A one-way ANOVA was conducted for the data presented in Figs. 2-5
and was followed by a post hoc to determine signiﬁcance between
speciﬁc experimental groups. Data focusing on diﬀerences between
non-diabetic and diabetic ﬁbroblasts (Figs. 2 & 3) used a Dunnett's post
hoc. The Dunnett's post hoc was chosen because our interest was in
comparing the diﬀerent experimental groups back to the “control”
group which was non-diabetic ﬁbroblasts in a non-diabetic matrix.
Experiments focusing on the impact of RAGE knockout (RKO) on cardiac ﬁbroblasts (Figs. 4 & 5) used a Sidak post hoc. The Sidak post hoc
was used due to the interest of only comparing signiﬁcance between the
same cell type (non-diabetic or non-diabetic RKO ﬁbroblasts) on different matrices.

4.5. Matrix contraction analysis
Matrix images were captured using an iBRIGHT imaging system
(Thermo Fisher Scientiﬁc) with a ruler for scale reference. Capture
speciﬁcations were set: Zoom: 1.2 and Focus: 2.16. Image J software
(NIH) was used to measure the area of the ring structure. The ring area
was determined to be the space from the center of the circular ring to
the inner perimeter of the ring structure. The scale for each image was
set using the ruler included in the image. Ring area for each sample was
normalized to the “control” which was designated as the average ring
area exhibited by untreated, non-diabetic ﬁbroblasts in non-diabetic
matrix (n = 9). This group was selected as the “control” because it best
represented how ﬁbroblasts would normally act when embedded into a
collagen matrix. The “control” value used to normalize other treatment
groups. The control value was determined by averaging the ring area of
all the untreated non-diabetic ﬁbroblasts in a non-diabetic matrix values together to generate one “control” value. This value was then used
to normalize the other treatment groups.
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4.6. Western blot analysis
Protein was isolated from matrices using modiﬁed Hunter's buﬀer
(MHB; 1% Trition X-100, 75 mM NaCl, 5 mM tris pH 7.4, 0.5 mM orthovanadate, 0.5 mM ECTA, 0.5 mM EGTA, 0.25% NP-40, and freshly
added Halt Protease Inhibitor Cocktail (100×; Thermo Fisher)).
Matrices were incubated on ice with MHB for 10 min, followed by
probe-sonication. Samples were centrifuged for 15 min at 32,000 xg at
4 °C, sonicated again, and then centrifuged at same conditions as before. Repeated sonication was necessary to ensure the matrix was disrupted to yield high protein concentrations. Protein concentration was
determined using a bicinchoninic acid assay (BCA; Pierce
Biotechnology) according to manufacturer's instructions. 20 μg of protein was used per sample for western blot analysis. Antibodies used
were as follow: monoclonal α-smooth muscle actin (α-SMA (1:400);
Sigma Aldrich 2547) and RAGE ((1:400) Santa Cruz sc-365,154).
Coomassie stain was used to label total protein and as a loading control
[39,40]. Western blots were visualized using an iBRIGHT imaging
system and Image J was used for analysis.
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